As of 2025-04-19, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.8x - 12.5x | 12.3x |
| Forward P/E multiples | 16.7x - 35.7x | 19.7x |
| Fair Price | (108.75) - (79.80) | (103.95) |
| Upside | -243.1% - -205.0% | -236.8% |
| Date | EV/EBITDA |